SVB Securities analyst Thomas Smith downgraded Galecto to Market Perform from Outperform with a price target of $2, down from $13.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GLTO:
- Galecto says Phase 2b GALACTIC-1 trial did not meet primary endpoint
- Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
- Galecto Reports Second Quarter Operating and Financial Results
- These 2 ‘Strong Buy’ Penny Stocks Could Go Boom, Say Analysts
- Galecto management to meet with Oppenheimer
